Anixa Biosciences, Inc. ANIX
NASDAQ
| 07/31/2026 | 04/30/2026 | 01/31/2026 | 10/31/2025 | 07/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -15.41% | 9.82% | 19.44% | 6.52% | 31.10% |
| Total Depreciation and Amortization | 11.11% | 11.11% | 11.11% | 0.00% | 200.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -22.56% | -41.21% | 6.33% | -14.37% | -33.76% |
| Change in Net Operating Assets | 332.93% | -31.43% | -74.55% | -38.64% | 86.49% |
| Cash from Operations | -17.14% | -15.83% | 10.12% | -35.38% | 42.83% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 70.59% | -81.98% | -54.57% | -24.57% | -130.58% |
| Cash from Investing | 70.59% | -81.98% | -54.57% | -24.57% | -130.58% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 4.43% | 71,750.00% | -- | -- | 612.50% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -68.29% | -9,658.82% | 9,658.82% | -87.05% | 11.51% |
| Cash from Financing | 0.36% | 6,838.89% | 10,011.76% | 230.19% | 1,194.63% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 80.96% | -108.17% | 238.99% | -645.65% | -280.43% |